Raf-1 expression may influence progression to androgen insensitive prostate cancer

Prostate

Volumn 64, Issue 1, 2005, Pages 101-107

  Mukherjee, R ^a,b   Bartlett, J M S ^a   Krishna, N S ^b   Underwood, M A ^b   Edwards, J ^a,c  

^a University Department of Surgery   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c University Department of Surgery   (United Kingdom)

Author keywords

AP 1; HER2; Hormone escaped prostate cancer; MAP kinase pathway

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER RELAPSE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE TARGETING; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE C FOS; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANDROGENS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE SIGNALING SYSTEM; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RAF; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 19544370522     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20211     Document Type: Article

References (24)

1. Sciarra A, Casale P, Colella D, Di Chiro C, Di Silverio F. Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy. Scand J Urol Nephrol 1999;33:211-216.
2. Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Semin Cancer Biol 1997;8:21-27.
3. Beemsterboer PMM, de Koning HJ, Birnie E, van der Maas PJ, Schroder FH. Advanced prostate cancer: Course, care, and cost implications. Prostate 1999;40:97-104.
4. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-1989.
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39.
6. Edwards J, Krishna NS, Witton CJ, Bartlett JMS. Gene amplifications associated with the development of hormone resistant prostate cancer. Clin Cancer Res 2003;9:5271-5281.
7. Yeh SY, Lin HK, Kang HY, Thin TH, Lin MF, Chang CS. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999;96:5458-5463.
8. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang FM, McCubrey JA. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 2000;88:229-279.
9. Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999;22:155-165.
10. Fu Z, Smith PC, Zhang LZ, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003;95:878-889.
11. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999;19:5143-5154.
12. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-284.
13. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997;11:342-345.
14. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277:7076-7085.
15. Franco OE, Onishi T, Yamakawa K, Arima K, Yanagawa M, Sugimura Y, Kawamura J. Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 2003;56:319-325.
16. Edwards J, Krishna NS, Mukherjee R, Bartlett JMS. The role of c-jun and c-fos expression in androgen-independent prostate cancer. J Pathol 2005 (in press).
17. Bell WC, Myers RB, Hosein TO, Oelschlager DK, Grizzle WE. The response of extracellular signal-regulated kinase (ERK) to androgen-induced proliferation in the androgen-sensitive prostate cancer cell line, LNCaP. Biotech Histochem 2003;78:11-16.
18. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, Lin MF. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003;107:478-485.
19. Mukherjee R, Nalagatla SK, Edwards J, Underwood M, Bartlett JMS. Type I receptor tyrosine-kinase activation of Raf-1 in androgen-escaped prostate cancer. A novel target for future therapy? J Urol 2004;171:161-161.
20. Edwards J, Krishna NS, Bartlett JMS. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-556.
21. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-285.
22. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ, Habib FK. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 2000;82:186-194.
23. Rochette-Egly C. Nuclear receptors: Integration of multiple signalling pathways through phosphorylation. Cell Signal 2003;15:355-366.
24. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Cleave ME. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997;272:17485-17494.